Coherus Oncology (CHRS) Non-Current Assets (2013 - 2026)

Coherus Oncology has disclosed Non-Current Assets across 14 years of filings, most recently posting $60.0 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $60.0 million, down 1.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $226.4 million (down 46.18% YoY), and the FY2025 annual result was $51.6 million, down 51.72% from the prior year.
• Non-Current Assets came in at $60.0 million for Q1 2026 at Coherus Oncology, up from $51.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $154.0 million in Q4 2023 to a low of $51.6 million in Q4 2025.
• The 5-year median for Non-Current Assets is $99.2 million (2022), against an average of $95.9 million.
• Across the five-year window, Non-Current Assets soared 57.3% in 2024 and sank 59.14% in 2025, its largest moves.
• Coherus Oncology's Non-Current Assets stood at $99.6 million in 2022, then jumped by 54.57% to $154.0 million in 2023, then slumped by 30.54% to $107.0 million in 2024, then slumped by 51.72% to $51.6 million in 2025, then grew by 16.17% to $60.0 million in 2026.
• The last three Non-Current Assets figures came in at $60.0 million (Q1 2026), $51.6 million (Q4 2025), and $55.6 million (Q3 2025), per Business Quant data.